HUMAN AMYLOID IMAGING CONFERENCE
January 11-13, 2017
The 11th Human Amyloid Imaging will take place in Miami, Florida on January 11-13, 2017. My co-organizers for the meeting once more were: Bill Klunk (University of Pittsburgh), Chet Mathis (University of Pittsburgh) and Bill Jagust (University of California, Berkeley).
At HAI 2016 we continued emphasizing ample lively discussion of core controversies such as: what does the presence of brain amyloid mean, how should it be measured, how does it change, and what does it portend? Our discussions primarily sprung from brief presentations by active investigators who report unpublished, cutting-edge research in human imaging of amyloid-beta and/or other biomarkers that pertain to Alzheimer’s-related disease.
To assemble HAI we accept and peer-review only the most recent, important work, abstract submissions. The 2016 meeting drew more than 325 attendees and showcased 112 posters from research groups spanning North America, Europe, East Asia, and Australia.
Meeting Programs as well as video recordings of the keynote presentations from past years are accessible from the Past Editions page of our site.
Research reports are complemented at HAI by Keynote presentations that are intended to cross disciplines and provide perspective from neuropathology, neurochemistry, psychology, neurology, molecular imaging, clinical trials and biomarker research.
In 2017, we are pleased to welcome three such presentations from Drs. Thomas Beach (Banner Sun Health Research Institute), Howard Feldman (University of California – San Diego) and Marc Diamond (UT Southwestern Medical Center). In addition to these, we will continue our lectures on basic methods in amyloid PET.
Please note that we will continue the extra half-day of sessions starting at noon on Wednesday, the 11th of January, 2017 (Sessions I & II). This extra time will be allotted for a few presentations on recent advances in tau PET. Tau PET technology is rapidly advancing, and while a separate, smaller “pre-meeting” was organized for 2015, the Organizers have decided to lengthen HAI by one-half day to accommodate the surge in interest in this new type of PET biomarker. This half-day of sessions is followed by the standard two full days of talks.
Until next year, we invite you to browse our site, review our past programs, speakers and posters. Hope to see you in 2017!
Keith A. Johnson, MD
Massachusetts General Hospital/Harvard Medical School
The 2016 edition of the HAI conference featured 38 podium presentations selected from submitted abstracts.
In 2017, we are pleased to welcome three keynote presentations from Thomas Beach (Banner Sun Health Research Institute), Howard Feldman (University of California – San Diego) and Marc Diamond (UT Southwestern Medical Center).
The 2016 meeting registered 151 abstract submissions and showcased 112 posters from research groups from North America, Europe, East Asia, and Australia.
Each session of podium presentations will be followed by a 30-40 minute panel discussion and Q&A session moderated by two co-chairs.
Attendees will have the opportunity to review the basic, fundamental principles of amyloid PET imaging, including radiochemistry of amyloid agents, radio-tracer synthesis, PET acquisition and data processing, including application of corrections for the partial volume effect and co-registration with structural data.
The concept of amyloid positive will be extensively discussed, and the attendees should be able to characterize the advantages and disadvantages of both dichotomized and continuous variable approaches to amyloid PET analyses with respect to specific purposes or intended uses of the outcome.
Attendees will have the opportunity to evaluate amyloid PET data in specific clinical and clinical research contexts, including review of typical findings in Alzheimer’s disease dementia, mild cognitive impairment due to Alzheimer’s disease, and in clinically normal individuals. These phenomena will also be related to familial forms of the disease and to non-AD processes such as fronto-temporal lobar degeneration and dementia with Lewy Bodies.
Particular attention will be given to the assessment of longitudinal amyloid PET data as it relates to methods of analysis and comparison to other domains of data, including structural and functional brain imaging data, and clinical and cognitive outcomes.
COUNTDOWN TO CONFERENCE
COUNTDOWN TO OPENING FOR ABSTRACT INTAKE